EVOK Stock Cash Flow Statements

Evoke Pharma Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Financing Cash Flow

Evoke Pharma Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30

operating activities
net income	-1,312,390	-1,267,218	-1,579,820	-1,987,401	-1,693,907	-1,867,917	-2,243,070	-1,803,221	-2,013,864	-2,233,380	-2,173,665	-1,672,362	-1,969,452	-2,290,643	-2,605,495	-2,267,862	-2,129,105	-6,967,395	-1,790,309	-1,418,228	-1,628,065	-2,114,096	-1,965,266	-1,760,632	-1,519,468
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	131,587	126,578	254,029	281,639	281,758	280,140	284,572	354,972	355,752	366,924	381,061	454,200	463,995	399,411	561,348	476,867	478,574	362,955	310,162	318,855	331,303	344,841	378,959	378,203	380,062
non-cash interest expense	126,027
non-cash lease expense				13,370	39,472	38,556	37,676	24,597
change in operating assets and liabilities:
accounts receivable	-19,515	-551,099	-778,833	560,833	-210,091	-336,511	-62,470	50,138	-309,327	53,267	-123,717	-73,027	-23,755	-70,616	-104,484
prepaid expenses and other current assets	227,486	299,916	222,045
inventories	51,357	44,011	-106,936
accounts payable and accrued expenses	-188,084	242,624	343,596																					23,776	344,743
accrued compensation	164,837	159,916	-1,058,129	494,341	216,737	212,681	-190,907	-125,836	188,328	116,467	-107,119	-291,473	189,314	192,682	-587,438
operating lease liabilities				-13,370	-39,472	-38,556	-37,676	-24,597
net cash from operating activities	-818,695	-820,615	-2,579,390	-1,106,104	-1,041,605	-1,206,373	-1,630,895	-2,506,325	-1,100,925	-1,373,707	-1,615,030	-1,997,198	-5,892,138	-1,510,489	-2,953,119	-1,711,504	-1,810,528	-1,556,080	-1,551,895	-1,147,690	-1,059,090	-1,628,427	-1,926,886	-1,248,914	-1,149,938
financing activities
proceeds from february 2024 offering, net of issuance costs	0	-1	6,718,212
payment of february 2024 offering costs	0	0	-426,293
proceeds from march 2024 warrant amendment, net of issuance costs
proceeds from june 2024 warrant amendment, net of issuance costs
payment of august 2024 shelf registration statement offering costs
proceeds from september 2024 exercise price warrant amendment, net of issuance costs
proceeds from september 2024 warrant amendment, net of issuance costs
proceeds from exercise of pre-funded warrants
redemption of fractional shares due to reverse stock split
net cash from financing activities	2,979,891	295,696	7,542,719					0	0	7,123,455	171,521	0	313,107	45,454	13,070,154	3,499,787	100,792	5,413,284	21,250	306,721	123,813	5,039,956	636,432	0	1,186,777
net increase in cash and cash equivalents	2,161,196	-524,919	4,963,329					-2,506,325	-1,100,925	5,749,748	-1,443,509	-1,997,198	-5,579,031	-1,465,035	10,117,035	1,788,283	-1,709,736			-840,969	-935,277				36,839
cash and cash equivalents at beginning of period	0	0	4,739,426	0	0	0	9,843,699	0	0	0	9,144,710	0	0	0	8,068,939	0	0	0	5,663,833	0	0	0	5,319,004	0	0
cash and cash equivalents at end of period	2,161,196	-524,919	9,702,755	-1,225,400	-1,041,605	-1,206,373	8,212,804	-2,506,325	-1,100,925	5,749,748	7,701,201	-1,997,198	-5,579,031	-1,465,035	18,185,974	1,788,283	-1,709,736	3,857,204	4,133,188	-840,969	-935,277	3,411,529	4,028,550	-1,248,914	36,839
supplemental disclosure of non-cash financial activities
august 2024 shelf registration statement costs included in accounts payable and accrued expenses
september 2024 exercise price warrant amendment costs included in accounts payable and accrued expenses
september 2024 warrant amendment costs included in accounts payable and accrued expenses
raw materials	-25,816	0	283,283
finished goods	-25,541	168,456	93,026
total inventories	-51,357	-44,011	588,776
proceeds from amendment and exercise of series b warrants, net of issuance costs		295,697	1,250,800
warrant amendment costs included in accounts payable and accrued expenses
interest expense			124,658
supplemental disclosure of non-cash financing activities
offering costs included in accounts payable			20,926
work in process			212,467
prepaid expenses and other assets																-658,386	-193,579	228,042	227,089	229,299	-631,471	143,197	142,299	109,739	-355,275
inventory
accrued interest payable
proceeds from issuance of common stock from atm								0			171,521	0
payment of atm offering costs
cash paid for offering costs
net cash (used)/provided by financing activities
net (decrease)/ increase in cash and cash equivalents
non-cash financing activities
public offering costs included in accounts payable and accrued expenses
operating lease right-of-use asset obtained in exchange for operating lease liabilities
common stock options				-15,369	-6,000	76,250	569,351	0	0	-4,921,615	5,413,466	-136,874	-377,374	135,448	5,392,259	-195,806	-13,306	297,000	3,989,371	0	-118,500	-439,753	3,672,624	0	0
total excluded securities				-15,369	-6,000	76,250	569,351	0	0	-4,933,615	5,425,466	-136,874	-539,580	135,448	7,234,138	-188,280	-547,267	-60,719	6,727,646	17,706	-111,206	-445,879	6,392,311	26,879	-130,612
prepaid expenses, inventory and other assets					255,737	151,193	206,079		343,521	318,355	227,100		352,046	344,250	359,617
accounts payable and other accrued expenses
accrued interest expense					126,028	124,657	123,288	126,027	126,028	124,657	123,288	125,065	126,028	125,619	122,589
payment of common stock offering costs from atm
net (decrease)/increase in cash and cash equivalents
supplemental disclosure of non-cash investing and financing activities
operating lease right-of-use assets obtained in exchange for operating lease liabilities
accounts payable and other current liabilities						229,384	251,613	-86,378	208,637	-119,997	58,022	307,773	-30,314	-201,192	-604,126		-19,860	-179,682	-298,837		869,143	-2,369	-482,878
net decrease in cash and cash equivalents						-1,206,373	-1,630,895												-1,530,645				-1,290,454
warrants to purchase common stock											12,000	0	-162,206	0	1,841,879	0	-478,598	-393,084	2,713,561	0	0	0	2,713,561	0	-84,000
reserve for obsolete inventory
forgiveness of paycheck protection loan and accrued interest												0	0	-962	-104,168
milestone payable												0
proceeds from issuance of common stock												0	0				-21,250	3,309,116	21,250	306,721	123,813	5,039,956	636,432	0	1,186,777
payment of common stock offering costs
proceeds from issuance of common stock from exercise of stock options													0
deferred rent expense															9,038
proceeds from issuance of common stock from employee stock purchase plan																1
proceeds from issuance of common stock from stock options exercises
proceeds from paycheck protection program																0	0
proceeds from eversana line of credit																3,000,000	0
employee stock purchase plan																7,526	-55,363	35,365	24,714	17,706			6,126	8,088	-16,447
proceeds from issuance of common stock, net of cost of 1,304,846															13,070,154
accounts payable and accrued liabilities
milestone expense																	0
accrued interest
proceeds from issuance of common stock from stock option exercised
change in fair value of warrant liability																								0	0
reclassification of warrant liability to equity due to amendment of warrants																								0	0
common stock subject to repurchase
reclassification of warrant liability to equity due to exercise of warrants
non-cash interest
financing costs allocated to warrant liability
payment on bank loan
proceeds from issuance of common stock and warrants
supplemental disclosure of cash flow information
interest paid
fair value of warrants issued to placement agent
deferred financing costs paid in prior year
proceeds from bank line of credit
payment on bank line of credit
costs paid in connection with loan origination
cash paid for interest
non-cash financing activities deferred financing costs paid in prior year
other assets
issuance of series a convertible preferred stock warrants
conversion of series a convertible preferred stock to common stock at the initial public offering
change in fair value of purchase right liability
proceeds from convertible promissory note
proceeds from bank line of credit and loan advances
proceeds from issuance of preferred stock and purchase rights
proceeds from exercise of stock options
supplemental disclosures of cash flow information
conversion of convertible promissory note and accrued interest to series a convertible preferred stock
gross proceeds
underwriting discounts and commissions and non-accountable expense allowance
total offering costs
net proceeds

We provide you with 20 years of cash flow statements for Evoke Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Evoke Pharma stock. Explore the full financial landscape of Evoke Pharma stock with our expertly curated income statements.

The information provided in this report about Evoke Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.